A comprehensive platform for contract research laboratory services bundled with cutting-edge bioinformatics for cancer drug efficacy screening, biomarker discovery and patient stratification
A UK company has extensive knowledge of pre/clinical drug efficacy screening experiments, vast omics datasets and bioinformatics, supporting discovery and validation of various links in oncology. Laboratory experiments bundled with cloud-based bioinformatics and novel patient data are on offer. Biopharma companies and consultants who need genetics-aided cancer research or clinical decision support for cancer treatment personalisation are sought for commercial agreements with technical assistance
Type of partner sought: biopharma industry and healthcare providers. Specific activity of partner sought: oncology. Role of partner sought: non-confidential descriptions of problems encountered are welcome. Jointly, plans can be made around combining the partners’ and the existing UK data, and designing approaches to problem solving.
An East of England company has developed a genomic platform to improve cancer treatment outcomes through advanced genetic screening technology. It aims at assisting both clinical oncologists and the researchers working on future treatments. For cancer patients, it aids in selecting the right cancer treatments and predicts the risk of relapse, comparing patients’ gene markers against an oncology knowledgebase of over 1200 gene-based cancer therapies. For biopharmaceutical research, the company offers product bundles of laboratory experiments and bioinformatics. The products include: Pre-clinical drug screening - Pre/clinical drug sensitivity screening (laboratory experiments using cell lines or animal models) with bioinformatics as a bundled product. The bioinformatics part includes study design and discovery analytics after generating the results. Thousands of publicly available cell banks (including CCLE (Cancer Cell Line Encyclopedia) and ATCC (American Type Culture Collection) and proprietary cell lines offer a wide variety to design the ideal drug screening experiments. Biomarker analytics - The platform offers 300+ multi-omic analytics workflows that are validated in 10,000+ patients in Cambridge. Genome analytics for biomarker validation includes DNA/RNA-Seq data from next-gen sequencing (whole genomes, exomes and gene panels), SNP (single nucleotide polymorphisms) / microarrays, and other technologies. Proteomic mass spectrometry is also offered as part of the standard analytics package; - Sequencing services, SNP genotyping, mass spectrometry, and other technologies are also offered through central laboratories either separately or bundled with other products. Genetics-aided clinical trials - The Platform’s biomarker workflows offer clinical trial design, patient selection, and response stratification in oncology; - These workflows aid in the selection of biomarkers and their ideal thresholds for patient selection. Access to Novel Clinical-Genomic data - The platform has access to a network of hospitals and patient data with required consent to be used in clinical R&D. Customers may request access to data for their R&D projects or engage the company to collect novel data; - The data collection and distribution follows global standards for data security and ethics. The costs will be determined based on the project’s needs. Hospitals, Central Diagnostic Labs For hospitals and diagnostic labs, the platform offers genetics-aided clinical decision support in oncology. - The Platform’s ready-to-use workflows could help generate clinical diagnostic reports for cancer treatment selection and relapse/response assessment; - Internal genomic data (e.g., gene panels or exomes) or central sequencing labs; - 1200+ genetics-aided therapy options for determining positive or adverse response and the probability of relapse, prior to and during the treatment. The company now seeks Biopharma companies and healthcare consultants for commercial agreements with technical assistance. The platform’s data analytics supplements its customers’ in-house bioinformatics expertise by freeing up their time for exploratory research and minimising their effort on routine analysis. The platform is well suited for new knowledge discovery. The partners’ and/or UK databases can be combined and the UK company will assist with experiment design and data analysis.
Advantages and innovations
The platform’s data analytics supplements its customers’ in-house bioinformatics expertise by freeing up their time for exploratory research and minimising their effort on routine analysis. The sheer number of datasets and analytics workflows accessed by the UK company fills many gaps in the state of the art.
Already on the market
Intellectual Property Rights (IPR)
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below